RegeneRx to receive EU patent for neural injury drug
Insight Weekly: Loan delinquencies up; US money supply falls; coal employment grows
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
RegeneRx Biopharmaceuticals Inc.'s neural injury drug RGN-352 is set to receive patent protection in Europe.
The European Patent Office notified the company of its intent to grant patent protection through March 26, 2030.
